KLRA - Company ID 0002096997
Kailera Therapeutics, Inc. trades as KLRA and has a market capitalization of $2.76 B, making it the #1908 largest US-listed company by market value. This page tracks Kailera Therapeutics, Inc. through 52 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13D | - | 2026-04-23 |
| SCHEDULE 13D | - | 2026-04-23 |
| Insider trade | 4 | 2026-04-22 |
| Insider trade | 4 | 2026-04-22 |
| Insider trade | 4 | 2026-04-20 |
| Insider trade | 4 | 2026-04-20 |
A live webcast will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI acted as joint book-running managers for the offering. William Blair acted as lead manager for the offering.
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are acting as joint book-running managers for the offering. William Blair is acting as lead manager for the offering.
The largest companies sharing Kailera Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Kailera Therapeutics, Inc. (KLRA) has a market capitalization of $2.76 B as of 2026-07-09, ranking #1908 among US-listed companies.